BMYY
BeiGene Limited
Is BMYY Halal?
BeOne Medicines' current filing fails the examined liquidity and receivables screens; oncology medicines remain generally permissible but product and legacy-ticker questions require review.
What You Should Know
BMYY is a preserved legacy BeiGene alias for BeOne Medicines. The audited December 31, 2025 Form 10-K reports USD 8,188.573 million of assets, USD 1,992.844 million of conservative debt and leases, USD 4,547.530 million of cash, USD 865.080 million of receivables and USD 5,343.033 million of revenue. Debt/assets is 24.34%, liquidity/assets is 55.53% and receivables-plus-cash/assets is 66.12%; the examined financial screens fail. The issuer changed its legal name to BeOne Medicines and its Nasdaq ADS symbol to ONC; the BMYY URL remains preserved.
⚠️ Concerns
- •Liquidity/assets is 55.53%, above the examined limits
- •Receivables-plus-cash/assets is 66.12%
- •Drug ingredients, excipients, cell lines and research methods require product-specific evidence
- •BMYY is a legacy alias for BeOne Medicines/ONC; the URL is unchanged
Current quantitative Sharia screen
Based on Annual Report on Form 10-K figures for the period ended 2025-12-31; calculated 2026-07-15.
1,992,844 / 8,188,573
4,547,530 / 8,188,573
5,412,610 / 8,188,573
70,505 / 5,343,033
- Financial
- Fails
- Overall
- Fails
Debt/assets is 24.34%, liquidity/assets is 55.53% and receivables-plus-cash/assets is 66.12%; liquidity and receivables exceed the examined FTSE limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 55.53% and receivables-plus-cash/assets is 66.12%, above the examined MSCI total-assets limits.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 55.53%, above the examined Malaysia liquidity limit; this is a calculation, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A licensed historical market-cap series is not stored, so market-cap denominator methods are not calculated.
Business-activity disclosure
BeOne Medicines develops and commercializes oncology medicines. Pharmaceutical research and treatment are generally permissible, while product ingredients, research methods, licensing, pricing and access require qualitative review.
Limitation: The filing does not provide a school-specific prohibited-revenue numerator for product ingredients, research activities or royalty arrangements.
Purification
Interest income is disclosed, but no scholar-approved purification percentage is inferred from the reported cash and money-market holdings.
Inputs, assumptions and primary sources
- Amounts are USD thousands from BeOne Medicines' audited consolidated 2025 Form 10-K.
- Debt includes short- and long-term debt plus operating lease liabilities as a conservative financing proxy; sale-of-future-royalties liabilities are not counted as conventional debt.
- Cash and cash equivalents include money-market funds; the filing reports no short-term investments at year-end, so securities are not double-counted.
- BMYY is a preserved legacy BeiGene alias. The issuer changed its name to BeOne Medicines and its Nasdaq ADS symbol to ONC; the existing URL remains unchanged.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →